10 XP 0   0   5  
0coffee
Main menu
3rd party ad coffee SUPPORTERis ad-free.

ATXI (Avenue Therapeutics Inc) Stock Analysis
Buy, Hold or Sell?

Let's analyze Avenue Therapeutics Inc together

I guess you are interested in Avenue Therapeutics Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

  • πŸ“Š Fundamental Analysis (FA) – Avenue Therapeutics Inc’s Financial Insights
  • πŸ“ˆ Technical Analysis (TA) – Avenue Therapeutics Inc’s Price Targets

I'm going to help you getting a better view of Avenue Therapeutics Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

Get notifications about Avenue Therapeutics Inc

I send you an email if I find something interesting about Avenue Therapeutics Inc.

1. Quick Overview

1.1. Quick analysis of Avenue Therapeutics Inc (30 sec.)










1.2. What can you expect buying and holding a share of Avenue Therapeutics Inc? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
$0.32
Expected worth in 1 year
$-4.39
How sure are you?
33.3%

+ What do you gain per year?

Total Gains per Share
$-4.70
Return On Investment
-1,622.4%

For what price can you sell your share?

Current Price per Share
$0.29
Expected price per share
$0 - $1.22
How sure are you?
50%
3rd party ad coffee SUPPORTERis ad-free.

2. Detailed Analysis

2.1. Valuation of Avenue Therapeutics Inc (5 min.)




Live pricePrice per Share (EOD)
$0.29
Intrinsic Value Per Share
$-80.59 - $-7.14
Total Value Per Share
$-80.27 - $-6.82

2.2. Growth of Avenue Therapeutics Inc (5 min.)




Is Avenue Therapeutics Inc growing?

Current yearPrevious yearGrowGrow %
How rich?$654k$3.2m-$2.6m-399.4%

How much money is Avenue Therapeutics Inc making?

Current yearPrevious yearGrowGrow %
Making money-$10.3m$2m-$12.4m-119.7%
Net Profit Margin0.0%0.0%--

How much money comes from the company's main activities?

2.3. Financial Health of Avenue Therapeutics Inc (5 min.)




2.4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#768 / 913

Most Revenue
#865 / 913

Most Profit
#452 / 913

Most Efficient
#266 / 913
3rd party ad coffee SUPPORTERis ad-free.

3. Summary and Key Metrics

3.1. What can you expect buying and holding a share of Avenue Therapeutics Inc?

Welcome investor! Avenue Therapeutics Inc's management wants to use your money to grow the business. In return you get a share of Avenue Therapeutics Inc.

First you should know what it really means to hold a share of Avenue Therapeutics Inc. And how you can make/lose money.

Speculation

The Price per Share of Avenue Therapeutics Inc is $0.29. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Avenue Therapeutics Inc.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Avenue Therapeutics Inc, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $0.32. Based on the TTM, the Book Value Change Per Share is $-1.18 per quarter. Based on the YOY, the Book Value Change Per Share is $-0.19 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Avenue Therapeutics Inc.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps-5.05-1,742.2%-5.05-1,742.2%0.94323.2%-4.21-1,452.0%-4.62-1,594.0%
Usd Book Value Change Per Share-1.18-405.6%-1.18-405.6%-0.19-64.0%0.1343.1%0.0412.2%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share-1.18-405.6%-1.18-405.6%-0.19-64.0%0.1343.1%0.0412.2%
Usd Price Per Share0.16-0.16-1.16-3.56-2.98-
Price to Earnings Ratio-0.03--0.03-1.24--0.49--0.39-
Price-to-Total Gains Ratio-0.14--0.14--6.25--0.96--0.72-
Price to Book Ratio0.51-0.51-0.78-1.98--0.81-
Price-to-Total Gains Ratio-0.14--0.14--6.25--0.96--0.72-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share0.29
Number of shares3448
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share-1.180.13
Usd Total Gains Per Share-1.180.13
Gains per Quarter (3448 shares)-4,055.58431.44
Gains per Year (3448 shares)-16,222.321,725.75
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-16222-16232017261716
20-32445-32454034513442
30-48667-48676051775168
40-64889-64898069036894
50-81112-81120086298620
60-97334-9734201035410346
70-113556-11356401208012072
80-129779-12978601380613798
90-146001-14600801553215524
100-162223-16223001725717250

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.01.00.00.0%1.02.00.033.3%1.04.00.020.0%1.08.00.011.1%1.08.00.011.1%
Book Value Change Per Share0.01.00.00.0%1.02.00.033.3%2.03.00.040.0%3.06.00.033.3%3.06.00.033.3%
Dividend per Share0.00.01.00.0%0.00.03.00.0%0.00.05.00.0%0.00.09.00.0%0.00.09.00.0%
Total Gains per Share0.01.00.00.0%1.02.00.033.3%2.03.00.040.0%3.06.00.033.3%3.06.00.033.3%
3rd party ad coffee SUPPORTERis ad-free.

3.2. Key Performance Indicators

The key performance indicators of Avenue Therapeutics Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---1.176-1.1760%-0.186-84%0.125-1040%0.035-3425%
Book Value Per Share--0.3180.3180%1.495-79%1.591-80%1.174-73%
Current Ratio--1.5471.5470%1.913-19%3.823-60%3.109-50%
Debt To Asset Ratio--0.6460.6460%0.523+24%0.362+79%45.970-99%
Debt To Equity Ratio--0.7560.7560%0.917-18%0.501+51%0.295+157%
Dividend Per Share----0%-0%-0%-0%
Enterprise Value--917681.120917681.1200%5663784.440-84%10502976.184-91%12506891.331-93%
Eps---5.052-5.0520%0.937-639%-4.211-17%-4.623-9%
Ev To Ebitda Ratio--0.2260.2260%-0.706+412%-1.126+597%-1.192+626%
Ev To Sales Ratio--infinfnan%infnan%infnan%infnan%
Free Cash Flow Per Share---6.062-6.0620%-3.476-43%-5.376-11%-4.639-23%
Free Cash Flow To Equity Per Share---2.398-2.3980%1.348-278%0.323-843%0.324-840%
Gross Profit Margin--1.4021.4020%1.000+40%1.080+30%1.045+34%
Intrinsic Value_10Y_max---7.141--------
Intrinsic Value_10Y_min---80.589--------
Intrinsic Value_1Y_max---3.133--------
Intrinsic Value_1Y_min---6.119--------
Intrinsic Value_3Y_max---7.570--------
Intrinsic Value_3Y_min---20.189--------
Intrinsic Value_5Y_max---9.787--------
Intrinsic Value_5Y_min---36.127--------
Market Cap595636.800+44%330681.120330681.1200%2534784.440-87%7333776.184-95%6132804.369-95%
Net Profit Margin----0%-0%-0%-0%
Operating Margin----0%-0%-0%-0%
Operating Ratio----0%-0%-0%-0%
Pb Ratio0.911+44%0.5060.5060%0.776-35%1.980-74%-0.810+260%
Pe Ratio-0.057-80%-0.032-0.0320%1.238-103%-0.486+1424%-0.394+1137%
Price Per Share0.290+44%0.1610.1610%1.160-86%3.556-95%2.978-95%
Price To Free Cash Flow Ratio-0.048-80%-0.027-0.0270%-0.334+1156%-0.757+2751%-0.610+2196%
Price To Total Gains Ratio-0.247-80%-0.137-0.1370%-6.251+4467%-0.956+598%-0.723+428%
Quick Ratio--1.4911.4910%1.874-20%3.721-60%3.394-56%
Return On Assets---5.609-5.6090%0.299-1975%-2.137-62%-45.039+703%
Return On Equity---6.559-6.5590%0.524-1351%-2.606-60%-1.518-77%
Total Gains Per Share---1.176-1.1760%-0.186-84%0.125-1040%0.035-3425%
Usd Book Value--654000.000654000.0000%3266000.000-80%3306000.000-80%2432888.889-73%
Usd Book Value Change Per Share---1.176-1.1760%-0.186-84%0.125-1040%0.035-3425%
Usd Book Value Per Share--0.3180.3180%1.495-79%1.591-80%1.174-73%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Enterprise Value--917681.120917681.1200%5663784.440-84%10502976.184-91%12506891.331-93%
Usd Eps---5.052-5.0520%0.937-639%-4.211-17%-4.623-9%
Usd Free Cash Flow---12451000.000-12451000.0000%-7596000.000-39%-11133800.000-11%-9579333.333-23%
Usd Free Cash Flow Per Share---6.062-6.0620%-3.476-43%-5.376-11%-4.639-23%
Usd Free Cash Flow To Equity Per Share---2.398-2.3980%1.348-278%0.323-843%0.324-840%
Usd Market Cap595636.800+44%330681.120330681.1200%2534784.440-87%7333776.184-95%6132804.369-95%
Usd Price Per Share0.290+44%0.1610.1610%1.160-86%3.556-95%2.978-95%
Usd Profit---10377000.000-10377000.0000%2048000.000-607%-8538600.000-18%-9403777.778-9%
Usd Revenue----0%-0%-0%-0%
Usd Total Gains Per Share---1.176-1.1760%-0.186-84%0.125-1040%0.035-3425%
 EOD+5 -3MRQTTM+0 -0YOY+7 -265Y+5 -2810Y+6 -27

3.3 Fundamental Score

Let's check the fundamental score of Avenue Therapeutics Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-0.057
Price to Book Ratio (EOD)Between0-10.911
Net Profit Margin (MRQ)Greater than00.000
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than11.491
Current Ratio (MRQ)Greater than11.547
Debt to Asset Ratio (MRQ)Less than10.646
Debt to Equity Ratio (MRQ)Less than10.756
Return on Equity (MRQ)Greater than0.15-6.559
Return on Assets (MRQ)Greater than0.05-5.609
Total5/10 (50.0%)

3.4 Technical Score

Let's check the technical score of Avenue Therapeutics Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5015.892
Ma 20Greater thanMa 500.643
Ma 50Greater thanMa 1001.096
Ma 100Greater thanMa 2001.517
OpenGreater thanClose0.300
Total1/5 (20.0%)

4. In-depth Analysis

4.1 About Avenue Therapeutics Inc

Avenue Therapeutics, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of neurologic diseases. Its product candidates include AJ201, which is in a Phase 1b/2a clinical trial for the treatment of spinal and bulbar muscular atrophy; intravenous tramadol for the treatment of post-operative acute pain; and BAER-101 for the treatment of epilepsy and panic disorders. The company was incorporated in 2015 and is based in Bay Harbor Islands, Florida. Avenue Therapeutics, Inc. is a subsidiary of Fortress Biotech, Inc.

Fundamental data was last updated by Penke on 2025-03-23 00:07:04.

4.2 In-depth Summary

4.2.1. Financial Health Summary

Profitability Details
 Compared to previous yearCompared to industry
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
Liquidity Details
 Compared to previous yearCompared to industry
The company is able to pay all its short-term debts.
The company is able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

4.2.2. Valuation Summary

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is cheap.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.
3rd party ad coffee SUPPORTERis ad-free.

4.3 Financial Health

4.3.1. Profitability

4.3.1 Profitability
4.3.1.1. Net Profit Margin

Measures how much net profitΒ Avenue Therapeutics Inc earns for each $1 of revenue.

  • Above 10% is considered healthy but always compareΒ Avenue Therapeutics Inc to theΒ Biotechnology industry mean.
  • A Net Profit Margin of 0.0%Β means thatΒ $0.00 for each $1Β in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Avenue Therapeutics Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-0.0%
TTM-5Y-0.0%
5Y-10Y-0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--109.6%+109.6%
TTM--187.7%+187.7%
YOY--206.2%+206.2%
5Y--404.0%+404.0%
10Y--526.8%+526.8%
4.3.1.2. Return on Assets

Shows howΒ efficientΒ Avenue Therapeutics Inc is using its assets to generate profit.

  • Above 5% is considered healthyΒ but always compareΒ Avenue Therapeutics Inc to theΒ Biotechnology industry mean.
  • -560.9% Return on Assets means thatΒ Avenue Therapeutics Inc generatedΒ $-5.61 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Avenue Therapeutics Inc:

  • The MRQ is -560.9%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -560.9%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-560.9%TTM-560.9%0.0%
TTM-560.9%YOY29.9%-590.8%
TTM-560.9%5Y-213.7%-347.2%
5Y-213.7%10Y-4,503.9%+4,290.2%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-560.9%-14.4%-546.5%
TTM-560.9%-14.8%-546.1%
YOY29.9%-14.6%+44.5%
5Y-213.7%-15.6%-198.1%
10Y-4,503.9%-18.0%-4,485.9%
4.3.1.3. Return on Equity

Shows how efficient Avenue Therapeutics Inc is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compareΒ Avenue Therapeutics Inc to theΒ Biotechnology industry mean.
  • -655.9% Return on Equity means Avenue Therapeutics Inc generated $-6.56Β for eachΒ $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Avenue Therapeutics Inc:

  • The MRQ is -655.9%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -655.9%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-655.9%TTM-655.9%0.0%
TTM-655.9%YOY52.4%-708.4%
TTM-655.9%5Y-260.6%-395.4%
5Y-260.6%10Y-151.8%-108.8%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-655.9%-17.7%-638.2%
TTM-655.9%-18.3%-637.6%
YOY52.4%-19.2%+71.6%
5Y-260.6%-24.3%-236.3%
10Y-151.8%-26.3%-125.5%
3rd party ad coffee SUPPORTERis ad-free.

4.3.2. Operating Efficiency of Avenue Therapeutics Inc.

4.3.2. Operating Efficiency
4.3.2.1. Operating Margin

MeasuresΒ how efficient Avenue Therapeutics Inc is operatingΒ .

  • Measures how much profit Avenue Therapeutics Inc makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compareΒ Avenue Therapeutics Inc to theΒ Biotechnology industry mean.
  • An Operating Margin of 0.0%Β means the company generated $0.00 Β for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Avenue Therapeutics Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-0.0%
TTM-5Y-0.0%
5Y-10Y-0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--224.0%+224.0%
TTM--281.8%+281.8%
YOY--227.6%+227.6%
5Y--398.6%+398.6%
10Y--512.4%+512.4%
4.3.2.2. Operating Ratio

Measures how efficient Avenue Therapeutics Inc is keepingΒ operating costsΒ low.

  • Below 1 is considered healthy (always compare toΒ Biotechnology industry mean).
  • An Operation Ratio of 0.00 means that the operating costs are $0.00 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Avenue Therapeutics Inc:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.000
TTM-YOY-0.000
TTM-5Y-0.000
5Y-10Y-0.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-2.323-2.323
TTM-3.192-3.192
YOY-3.069-3.069
5Y-5.143-5.143
10Y-7.010-7.010
3rd party ad coffee SUPPORTERis ad-free.

4.4.3. Liquidity of Avenue Therapeutics Inc.

4.4.3. Liquidity
4.4.3.1. Current Ratio

Measures if Avenue Therapeutics Inc is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare toΒ Biotechnology industry mean).
  • A Current Ratio of 1.55Β means the company has $1.55 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Avenue Therapeutics Inc:

  • The MRQ is 1.547. The company is able to pay all its short-term debts. +1
  • The TTM is 1.547. The company is able to pay all its short-term debts. +1
Trends
Current periodCompared to+/- 
MRQ1.547TTM1.5470.000
TTM1.547YOY1.913-0.366
TTM1.5475Y3.823-2.277
5Y3.82310Y3.109+0.715
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1.5473.741-2.194
TTM1.5473.895-2.348
YOY1.9134.507-2.594
5Y3.8235.739-1.916
10Y3.1096.099-2.990
4.4.3.2. Quick Ratio

Measures if Avenue Therapeutics Inc is able to pay off Short-term Debt but only usingΒ theΒ most liquid assets.

  • Above 1 is considered healthy butΒ always compareΒ Avenue Therapeutics Inc to theΒ Biotechnology industry mean.
  • A Quick Ratio of 1.49Β means the company can pay off $1.49 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Avenue Therapeutics Inc:

  • The MRQ is 1.491. The company is able to pay all its short-term debts with the most liquid assets. +1
  • The TTM is 1.491. The company is able to pay all its short-term debts with the most liquid assets. +1
Trends
Current periodCompared to+/- 
MRQ1.491TTM1.4910.000
TTM1.491YOY1.874-0.383
TTM1.4915Y3.721-2.230
5Y3.72110Y3.394+0.326
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1.4913.086-1.595
TTM1.4913.326-1.835
YOY1.8744.362-2.488
5Y3.7215.726-2.005
10Y3.3946.427-3.033
3rd party ad coffee SUPPORTERis ad-free.

4.5.4. Solvency of Avenue Therapeutics Inc.

4.5.4. Solvency
4.5.4.1. Debt to Asset Ratio

Measures how much %Β of Avenue Therapeutics IncΒ assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compareΒ Avenue Therapeutics Inc to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.65Β means that Avenue Therapeutics Inc assets areΒ financed with 64.6% credit (debt) and the remaining percentage (100% - 64.6%)Β is financed by its owners/shareholders.Β 

Let's take a look of the Debt to Asset Ratio trends of Avenue Therapeutics Inc:

  • The MRQ is 0.646. The company is able to pay all its debts by selling its assets. +1
  • The TTM is 0.646. The company is able to pay all its debts by selling its assets. +1
Trends
Current periodCompared to+/- 
MRQ0.646TTM0.6460.000
TTM0.646YOY0.523+0.124
TTM0.6465Y0.362+0.285
5Y0.36210Y45.970-45.608
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.6460.340+0.306
TTM0.6460.340+0.306
YOY0.5230.314+0.209
5Y0.3620.365-0.003
10Y45.9700.392+45.578
4.5.4.2. Debt to Equity Ratio

Measures ifΒ Avenue Therapeutics Inc is able toΒ pay off its debts by usingΒ shareholders equity.

  • Below 2 is considered healthy butΒ always compareΒ Avenue Therapeutics Inc to theΒ Biotechnology industry mean.
  • A Debt to Equity ratio of 75.6% means that company has $0.76 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Avenue Therapeutics Inc:

  • The MRQ is 0.756. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.756. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.756TTM0.7560.000
TTM0.756YOY0.917-0.161
TTM0.7565Y0.501+0.255
5Y0.50110Y0.295+0.207
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.7560.399+0.357
TTM0.7560.407+0.349
YOY0.9170.384+0.533
5Y0.5010.426+0.075
10Y0.2950.460-0.165
3rd party ad coffee SUPPORTERis ad-free.

4.6. Market Valuation

4.6.1. Earnings Per Share
4.6.2.1. Price to Earnings Ratio

MeasuresΒ how much money you payΒ for each share forΒ every $1 in earnings Avenue Therapeutics Inc generates.

  • Above 15 is considered overpriced butΒ always compareΒ Avenue Therapeutics Inc to theΒ Biotechnology industry mean.
  • A PE ratio of -0.03 means the investor is paying $-0.03Β for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Avenue Therapeutics Inc:

  • The EOD is -0.057. Based on the earnings, the company is expensive. -2
  • The MRQ is -0.032. Based on the earnings, the company is expensive. -2
  • The TTM is -0.032. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-0.057MRQ-0.032-0.026
MRQ-0.032TTM-0.0320.000
TTM-0.032YOY1.238-1.270
TTM-0.0325Y-0.486+0.454
5Y-0.48610Y-0.394-0.091
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-0.057-1.906+1.849
MRQ-0.032-2.688+2.656
TTM-0.032-3.245+3.213
YOY1.238-3.240+4.478
5Y-0.486-6.333+5.847
10Y-0.394-7.137+6.743
4.6.2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Avenue Therapeutics Inc:

  • The EOD is -0.048. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -0.027. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -0.027. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-0.048MRQ-0.027-0.021
MRQ-0.027TTM-0.0270.000
TTM-0.027YOY-0.334+0.307
TTM-0.0275Y-0.757+0.731
5Y-0.75710Y-0.610-0.147
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-0.048-2.455+2.407
MRQ-0.027-3.724+3.697
TTM-0.027-4.254+4.227
YOY-0.334-4.356+4.022
5Y-0.757-8.511+7.754
10Y-0.610-9.739+9.129
3rd party ad coffee SUPPORTERis ad-free.
4.6.2. Book Value per Share
4.6.2.1. Price to Book Ratio

Measures if the stock price ofΒ Avenue Therapeutics Inc is to cheap or to expensiveΒ compared to its book value.

  • At or below 1 is considered healthyΒ (always compare to Biotechnology industry mean).
  • A PB ratio of 0.51 means the investor is paying $0.51Β for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Avenue Therapeutics Inc:

  • The EOD is 0.911. Based on the equity, the company is cheap. +2
  • The MRQ is 0.506. Based on the equity, the company is cheap. +2
  • The TTM is 0.506. Based on the equity, the company is cheap. +2
Trends
Current periodCompared to+/- 
EOD0.911MRQ0.506+0.405
MRQ0.506TTM0.5060.000
TTM0.506YOY0.776-0.270
TTM0.5065Y1.980-1.475
5Y1.98010Y-0.810+2.791
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD0.9111.726-0.815
MRQ0.5062.254-1.748
TTM0.5062.433-1.927
YOY0.7762.441-1.665
5Y1.9803.776-1.796
10Y-0.8104.200-5.010
4.6.2. Total Gains per Share

4.7 Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Avenue Therapeutics Inc.

4.8.1. Institutions holding Avenue Therapeutics Inc

Institutions are holding 15.329% of the shares of Avenue Therapeutics Inc.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2024-12-31Ikarian Capital, LLC6.81620.03811400001400000
2024-12-31BOOTHBAY FUND MANAGEMENT, LLC2.00050.00241089410890
2024-12-31UBS Group AG0.385607920177728.9272
2024-12-31Tower Research Capital LLC0.15070.00013096135677.931
2024-12-31Wells Fargo & Co0.02430500-61-10.8734
2024-12-31Bank of America Corp0.0007014440
2024-12-31SBI Securities Co Ltd0.00040990
2024-12-31Moss Adams Wealth Advisors LLC000-11000-100
2024-12-31Sabby Management LLC000-63060-100
2024-12-31JPMorgan Chase & Co000-2-100
2024-12-31Northern Trust Investments N A000-68-100
2024-12-31Armistice Capital, LLC000-115000-100
Total 9.37840.0402192628-4956-2.6%

4.9.2. Funds holding Avenue Therapeutics Inc

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2025-01-31Fidelity Extended Market Index0.317506522-71-1.0769
2025-01-31Fidelity Series Total Market Index0.07710158400
2025-01-31Vanguard Institutional Extnd Mkt Idx Tr0.0301061800
2025-01-31Spartan Extended Market Index Pool E0.0035071710
2024-12-31NT Ext Equity Mkt Idx Fd - NL0.00030700
2024-12-31Northern Trust Extended Eq Market Idx0.00030600
2024-12-31NT Ext Equity Mkt Idx Fd - DC - NL - T20.00030600
2024-12-31NT Ext Equity Mkt Idx Fd - L0.00030600
2025-02-28State St US Extended Mkt Indx NL Cl C0.00010300
2024-09-30NT Ext Eq Mkt Indx Fd DC Lending Tier 500100
2024-06-30SSgA U.S. Total Market Index Strategy00100
2024-12-31NT Ext Eq Mkt Indx Fd DC Lend T400110
2024-12-31NT Ext Eq Mkt Indx Fd DC Lend T300110
Total 0.429508827+2+0.0%

5.3. Insider Transactions

Insiders are holding 25.225% of the shares of Avenue Therapeutics Inc.

DateOwnerTypeAmountPricePost Transaction AmountLink
2024-11-05Jay D KranzlerSELL612.24
3rd party ad coffee SUPPORTERis ad-free.

5. Financial Statements




5.1. Reversals in quarterly reports

I have detected a reversal (positive to negative, negative to positive) in the following values of the quarterly reports.

 2019-12-312020-12-312021-12-312022-12-312023-12-31
EBITDA  -26,26521,052-5,2131,482-3,731-4,292-8,02312,0754,052



5.2. Latest Balance Sheet

Balance Sheet of 2023-12-31. Currency in USD. All numbers in thousands.

Summary
Total Assets1,850
Total Liabilities1,196
Total Stockholder Equity1,582
 As reported
Total Liabilities 1,196
Total Stockholder Equity+ 1,582
Total Assets = 1,850

Assets

Total Assets1,850
Total Current Assets1,850
Long-term Assets0
Total Current Assets
Cash And Cash Equivalents 1,783
Other Current Assets 67
Total Current Assets  (as reported)1,850
Total Current Assets  (calculated)1,850
+/-0
Long-term Assets
Long-term Assets  (as reported)0
Long-term Assets  (calculated)0
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities1,196
Long-term Liabilities0
Total Stockholder Equity1,582
Total Current Liabilities
Accounts payable 401
Other Current Liabilities 795
Total Current Liabilities  (as reported)1,196
Total Current Liabilities  (calculated)1,196
+/-0
Long-term Liabilities
Long-term Liabilities  (as reported)0
Long-term Liabilities  (calculated)0
+/-0
Total Stockholder Equity
Common Stock3
Retained Earnings -90,928
Other Stockholders Equity 92,507
Total Stockholder Equity (as reported)1,582
Total Stockholder Equity (calculated)1,582
+/-0
Other
Capital Stock3
Cash and Short Term Investments 1,783
Common Stock Shares Outstanding 141
Liabilities and Stockholders Equity 1,850
Net Debt -1,783
Net Invested Capital 1,582
Net Working Capital 654



5.3. Balance Sheets Structured

Currency in USD. All numbers in thousands.

 Trend2023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-312015-12-31
> Total Assets 
14
197
22,170
4,525
8,915
3,245
3,960
6,845
1,850
1,8506,8453,9603,2458,9154,52522,17019714
   > Total Current Assets 
14
197
22,170
4,525
8,915
3,245
3,960
6,845
1,850
1,8506,8453,9603,2458,9154,52522,17019714
       Cash And Cash Equivalents 
14
197
11,782
2,671
8,745
3,132
3,763
6,708
1,783
1,7836,7083,7633,1328,7452,67111,78219714
       Short-term Investments 
0
0
10,000
0
0
0
0
0
0
00000010,00000
       Net Receivables 
0
0
0
0
0
0
90
0
0
0090000000
       Other Current Assets 
0
0
388
152
170
113
107
137
67
6713710711317015238800
   > Long-term Assets 
0
0
0
1,702
0
0
0
0
0
000001,702000
       Other Assets 
0
0
388
1,854
170
113
0
0
67
67001131701,85438800
> Total Liabilities 
5,149
8,445
2,790
5,156
2,115
886
509
3,579
1,196
1,1963,5795098862,1155,1562,7908,4455,149
   > Total Current Liabilities 
2,446
6,419
2,790
5,156
2,115
886
509
3,579
1,196
1,1963,5795098862,1155,1562,7906,4192,446
       Short-term Debt 
1,165
3,848
0
0
0
0
0
0
0
00000003,8481,165
       Short Long Term Debt 
3,868
3,848
0
0
0
0
0
0
0
00000003,8483,868
       Accounts payable 
491
506
2,737
3,576
368
172
362
150
401
4011503621723683,5762,737506491
       Other Current Liabilities 
114
314
53
1,580
1,747
714
147
3,429
795
7953,4291477141,7471,58053314114
   > Long-term Liabilities 
2,703
2,026
0
3,576
368
172
362
1
0
013621723683,57602,0262,703
       Long term Debt Total 
2,703
2,026
0
0
0
0
0
0
0
00000002,0262,703
> Total Stockholder Equity
-5,135
-8,248
19,380
-631
6,800
2,359
3,451
3,905
1,582
1,5823,9053,4512,3596,800-63119,380-8,248-5,135
   Common Stock
1
1
1
1
2
2
2
0
3
302221111
   Retained Earnings -90,928-80,551-76,999-73,268-68,117-42,209-20,661-8,403-5,226
   Accumulated Other Comprehensive Income 000000000
   Capital Surplus 
50
105
38,937
41,577
74,915
75,625
0
0
0
00075,62574,91541,57738,93710550
   Treasury Stock000000000



5.4. Balance Sheets

Currency in USD. All numbers in thousands.




5.5. Cash Flows

Currency in USD. All numbers in thousands.




5.6. Income Statements

Currency in USD. All numbers in thousands.


5.7. Latest Income Statement

Income Statement (annual), 2023-12-31. Currency in USD. All numbers in thousands.

Gross Profit (+$)
totalRevenue0
Cost of Revenue-0
Gross Profit00
 
Operating Income (+$)
Gross Profit0
Operating Expense-14,540
Operating Income-14,540-14,540
 
Operating Expense (+$)
Research Development10,361
Selling General Administrative4,179
Selling And Marketing Expenses4,175
Operating Expense14,54018,715
 
Net Interest Income (+$)
Interest Income126
Interest Expense-332
Other Finance Cost-0
Net Interest Income-206
 
Pretax Income (+$)
Operating Income-14,540
Net Interest Income-206
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-10,488-18,592
EBIT - interestExpense = -10,820
-10,488
-10,045
Interest Expense332
Earnings Before Interest and Taxes (EBIT)-10,488-10,156
Earnings Before Interest and Taxes (EBITDA)4,052
 
After tax Income (+$)
Income Before Tax-10,488
Tax Provision-0
Net Income From Continuing Ops-10,488-10,488
Net Income-10,377
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses14,540
Total Other Income/Expenses Net4,052206
 

Technical Analysis of Avenue Therapeutics Inc
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Avenue Therapeutics Inc. The general trend of Avenue Therapeutics Inc is BEARISH with 100.0% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Avenue Therapeutics Inc's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (-100.0%) Bearish trend (100.0%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Avenue Therapeutics Inc Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

SupportΒ is a price level at which demand for an asset is strong enough to prevent the price from falling further.
ResistanceΒ is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Avenue Therapeutics Inc.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 1.0697 < 1.22 < 1.22.

The bearish price targets are: .

Know someone who trades $ATXI? Share this with them.πŸ‘‡

Avenue Therapeutics Inc Daily Support & Resistance Chart
3rd party ad coffee SUPPORTERis ad-free.

2. Trend Indicators

2.1 Moving Averages

Shows theΒ moving averageΒ of the selected period.

  • Moving averages are laggingΒ trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Avenue Therapeutics Inc. The current mas is .

The long score for the Moving Averages is 0/14.
The longshort score for the Moving Averages is -14/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 < MA 50: The MA 20 is lower than the MA 50. -1
  • MA 20 < MA 100: The MA 20 is lower than the MA 100. -1
  • MA 20 < MA 200: The MA 20 is lower than the MA 200. -1
  • MA 50 trending down: The MA 50 is trending down. -1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 < MA 100: The MA 50 is lower than the MA 100. -1
  • MA 50 < MA 200: The MA 50 is lower than the MA 200. -1
  • MA 100 trending down: The MA 100 is trending down. -1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 < MA 200: The MA 100 is lower than the MA 200. -1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Avenue Therapeutics Inc Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows theΒ momentumΒ of theΒ selected period based on two moving averages.

  • MACD is aΒ lagging momentumΒ indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Avenue Therapeutics Inc. The current macd is -0.25147968.

The long score for the Moving Average Convergence/Divergence (MACD) is 1/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is -2/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Avenue Therapeutics Inc price going down in the near term. -2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Avenue Therapeutics Inc. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Avenue Therapeutics Inc price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending up: The MACD line is trending up. This indicates that the short-term moving average is rising faster than the long-term moving average, suggesting positive momentum in the market. This signals that buyers are becoming more active and confident, leading to potential price increases as traders anticipate further gains and are willing to buy at higher prices. +1
Avenue Therapeutics Inc Daily Moving Average Convergence/Divergence (MACD) ChartAvenue Therapeutics Inc Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Avenue Therapeutics Inc. The current adx is 47.12.

The long score for the Directional Movement Index (DMI) is 0/7.
The longshort score for the Directional Movement Index (DMI) is -4/(-7 +7).

  • PLUS_ID < MINUS_DI: The +DI line is below the -DI line. This indicates a bearish signal in the market, as the negative directional movement is currently stronger than the positive directional movement, showing that sellers have the upper hand. Market psychology suggests that traders are pessimistic, expecting further price decreases, and are more willing to sell Avenue Therapeutics Inc shares, leading to potential downward momentum in its price. -1
  • PLUS_ID < MINUS_DI && ADX > 25 && ADX trending up: The ADX is above 25 and indicates a strong bearish trend. The ADX is trending up, so the bearish trend is strengthening.
Avenue Therapeutics Inc Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • ShowsΒ the current trend.
  • ShowsΒ potential entry signals.
  • ShowsΒ Β potential exit signals.
  • Can be used to placeΒ trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Avenue Therapeutics Inc. The current sar is 0.43776804.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
Avenue Therapeutics Inc Daily Parabolic SAR Chart
3rd party ad coffee SUPPORTERis ad-free.

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentumΒ indicator, meaning the signals are instant.
  • RangesΒ between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Avenue Therapeutics Inc. The current rsi is 15.89. The current phase is Oversold in bear market.

The long score for the Relative Strength Index (RSI) is 1/13.
The longshort score for the Relative Strength Index (RSI) is 0/(-13 +13).

  • Oversold in bear market: Short-term excessive selling, potential for relief rally. Be cautious, consider taking short-term long positions. +1
  • Trending down: The RSI is trending down. -1
Avenue Therapeutics Inc Daily Relative Strength Index (RSI) ChartAvenue Therapeutics Inc Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

ComparesΒ a certain price to multiple prices ranging over time.

  • LeadingΒ momentumΒ indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • RangesΒ between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Avenue Therapeutics Inc. The current phase is Oversold in bear market.

The long score for the Stochastic Oscillator is 0/6.
The longshort score for the Stochastic Oscillator is -6/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH < 20: The STOCH %K is below 20 and oversold. -2
  • STOCH %K line < STOCH %D line: The STOCH %K line is below the STOCH %D line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Avenue Therapeutics Inc price going down in the near term. -2
  • Trending down: The STOCH %K is trending down. -1
Avenue Therapeutics Inc Daily Stochastic Oscillator ChartAvenue Therapeutics Inc Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero,Β the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Avenue Therapeutics Inc. The current cci is -81.16319395.

Avenue Therapeutics Inc Daily Commodity Channel Index (CCI) ChartAvenue Therapeutics Inc Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Avenue Therapeutics Inc. The current cmo is -75.98938999.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
Avenue Therapeutics Inc Daily Chande Momentum Oscillator (CMO) ChartAvenue Therapeutics Inc Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

Β Shows the current price relative to the highest high over the last 14 days.
Β 

  • Lagging momentum indicator
  • Ranging between 0 andΒ -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Avenue Therapeutics Inc. The current willr is -100.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is -1/(-1 +1).

  • WILLR < -80: The Williams %R is below -80. This indicates that the price is in oversold territory, suggesting a potential price correction or trend reversal to the upside. -1
Avenue Therapeutics Inc Daily Williams %R ChartAvenue Therapeutics Inc Daily Williams %R Chart
3rd party ad coffee SUPPORTERis ad-free.

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversoldΒ 

Score

Let's take a look at the Bollinger Bands of Avenue Therapeutics Inc.

Avenue Therapeutics Inc Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Avenue Therapeutics Inc. The current atr is 0.08258787.

Avenue Therapeutics Inc Daily Average True Range (ATR) ChartAvenue Therapeutics Inc Daily Average True Range (ATR) Chart
3rd party ad coffee SUPPORTERis ad-free.

5. Volume Indicators

5.1 On-Balance Volume (OBV)

Β Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Avenue Therapeutics Inc. The current obv is 15,529,677.

Avenue Therapeutics Inc Daily On-Balance Volume (OBV) ChartAvenue Therapeutics Inc Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Avenue Therapeutics Inc. The current mfi is 15.31.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -2/(-2 +2).

  • MFI < 50: -1
  • MFI < 20: -1
Avenue Therapeutics Inc Daily Money Flow Index (MFI) ChartAvenue Therapeutics Inc Daily Money Flow Index (MFI) Chart
3rd party ad coffee SUPPORTERis ad-free.

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Avenue Therapeutics Inc.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2024-11-07DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-11-08DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-11-11MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-11-13SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-11-14STOCH SHORT EXITThe %K line crosses above the %D line.
2024-11-15MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-11-20MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-11-25MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-11-26STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-11-27CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-11-29WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-12-02STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-12-03CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-12-04MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-12-06WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-12-09CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-12-10STOCH SHORT EXITThe %K line crosses above the %D line.
2024-12-11STOCH LONG EXITThe %K line crosses below the %D line.
2024-12-13WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-12-16CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-12-17BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-12-18STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-12-19SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-12-20STOCH LONG EXITThe %K line crosses below the %D line.
2024-12-23MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-12-24STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-12-26STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-12-27WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-12-31CCI LONG ENTRY SHORT CLOSE100 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2025-01-02DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH LONG EXITThe %K line crosses below the %D line.
2025-01-03STOCH SHORT EXITThe %K line crosses above the %D line.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2025-01-06STOCH LONG EXITThe %K line crosses below the %D line.
2025-01-08DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-01-13STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-01-14CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-01-15STOCH LONG EXITThe %K line crosses below the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2025-01-16MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2025-01-17STOCH SHORT EXITThe %K line crosses above the %D line.
2025-01-22STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2025-01-23STOCH SHORT EXITThe %K line crosses above the %D line.
2025-01-24SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2025-01-27SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-01-31STOCH SHORT EXITThe %K line crosses above the %D line.
2025-02-03STOCH LONG EXITThe %K line crosses below the %D line.
2025-02-04STOCH SHORT EXITThe %K line crosses above the %D line.
2025-02-06STOCH LONG EXITThe %K line crosses below the %D line.
2025-02-11STOCH SHORT EXITThe %K line crosses above the %D line.
2025-02-13MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2025-02-18WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-02-19CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-02-20STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-02-25CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-02-28MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-03-05STOCH SHORT EXITThe %K line crosses above the %D line.
2025-03-07STOCH LONG EXITThe %K line crosses below the %D line.
2025-03-10RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
2025-03-11STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-03-13CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-03-14STOCH SHORT EXITThe %K line crosses above the %D line.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2025-03-17MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2025-03-18STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2025-03-21STOCH SHORT EXITThe %K line crosses above the %D line.
2025-03-26STOCH LONG EXITThe %K line crosses below the %D line.

6.3. Candlestick Patterns

Avenue Therapeutics Inc Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Avenue Therapeutics Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5015.892
Ma 20Greater thanMa 500.643
Ma 50Greater thanMa 1001.096
Ma 100Greater thanMa 2001.517
OpenGreater thanClose0.300
Total1/5 (20.0%)
Penke
Good job! You gained 25 XP and 0   0   10 . What's next:
  • Share my analysis of Avenue Therapeutics Inc with someone you think should read this too:
  • Are you bullish or bearish on Avenue Therapeutics Inc? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Avenue Therapeutics Inc? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Avenue Therapeutics Inc

I send you an email if I find something interesting about Avenue Therapeutics Inc.


Comments

How you think about this?

Leave a comment

Stay informed about Avenue Therapeutics Inc.

Receive notifications about Avenue Therapeutics Inc in your mailbox!

3rd party ad coffee SUPPORTERis ad-free.